Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 4/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17558117 | 0.96 | MGLL (0.54) | MGLLCNR1ALDH1A1MAPTTHRB | |
| SCHEMBL17558160 | 0.88 | CNR1 (0.47) | MGLLCNR1ALDH1A1CNR2EPHX2 | |
| SCHEMBL17558159 | 0.88 | CNR1 (0.47) | MGLLCNR1ALDH1A1CNR2EPHX2 | |
| SCHEMBL30641883 | 0.87 | CNR2 (0.53) | CNR1CNR2 | |
| SCHEMBL17558145 | 0.87 | CNR2 (0.53) | CNR1CNR2 | |
| SCHEMBL19399339 | 0.86 | MGLL (0.52) | MGLLCNR1ALDH1A1MAPTTHRB | |
| SCHEMBL19376405 | 0.86 | HTR2A (0.51) | MGLLCNR1ALDH1A1MAPTTHRB | |
| SCHEMBL30641877 | 0.86 | HTR2A (0.51) | MGLLCNR1ALDH1A1MAPTTHRB | |
| SCHEMBL22693068 | 0.83 | CNR2 (0.50) | CNR1THRBCNR2 | |
| SCHEMBL17558124 | 0.82 | MGLL (0.52) | MGLLCNR1ALDH1A1MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844002-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-11-24 | — | — | US | disclosed |
| US-20190002393-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2019-01-03 | — | — | US | disclosed |
| US-20170275243-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275243-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844002-B2 | Lipids and lipid compositions for the delivery of active agents | LRAT, LIPA, LPAR1 | MGLL 89/4885CNR1 1487/4885ALDH1A1 1784/4885 |
| US-20170275243-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | LRAT, LPAR4, LPAR1 | MGLL 89/4885CNR1 1519/4885ALDH1A1 1896/4885 |
| US-20190002393-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | LRAT, LIPA, LPAR1 | MGLL 89/4885CNR1 1487/4885ALDH1A1 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.